CNS Pharmaceuticals (CNSP) Price & Analysis

Compare

1,089 Followers

CNSP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.66 - $221.40

Previous CloseN/A

Volume19.26M

Average Volume (3M)25.22K

Market Cap

$3.55M

Enterprise Value-$9.13M

Total Cash (Recent Filing)$13.05M

Total Debt (Recent Filing)$210.67K

Price to Earnings (P/E)―

Beta2.36

Next Earnings

Aug 18, 2025

EPS Estimate

-9.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-18.96

Shares Outstanding529,829

10 Day Avg. Volume25,913

30 Day Avg. Volume25,216

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-2.57

Enterprise Value/Revenue-2.91K

Enterprise Value/Gross Profit8.84K

Enterprise Value/Ebitda0.58

Forecast

1Y Price Target

$84.00

Price Target Upside1153.73% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Financial StabilityCNS Pharmaceuticals has been able to raise approximately $15M, providing sufficient cash runway into the first half of 2025.

Management PerformanceManagement, over the past few years, has done a remarkable job, in our view, navigating the company through its most challenging period, which was compounded by both challenging biotech markets and a difficult financing environment in general.

Bears Say

Clinical Trial ResultsBerubicin, a brain penetrating anthracycline, failed on the primary of overall survival vs. lomustine in the P2 second line glioblastoma study.

Stock PerformanceShares are down ~60% on the news.

CNS Pharmaceuticals News

CNS Pharmaceuticals Inc trading halted, news pending

19:50 EDT CNS Pharmaceuticals (CNSP) Inc trading halted, news pending Published first on TheFly – the ultimate source...

19d ago

CNSP

Upcoming Stock Splits This Week (July 21 to July 25) – Stay Invested

These are the upcoming stock splits for the week of July 21 to July 25 on TipRanks’ Stock Splits...

20d ago

GVH

CNS Pharmaceuticals announces 1-for-12 reverse stock split

CNS Pharmaceuticals (CNSP) announced a 1-for-12 reverse split of its common stock. Beginning on July 22, 2025, the...

22d ago

CNSP

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals ( ($CNSP) ) has shared an announcement. On July 17, 2025, CNS Pharmaceuticals, Inc. announced a...

18d ago

CNSP

CNS Pharmaceuticals Posts Investor Presentation on Brain Cancer

An announcement from CNS Pharmaceuticals ( ($CNSP) ) is now available. On July 15, 2025, CNS Pharmaceuticals announced...

25d ago

CNSP

CNS Pharmaceuticals to present on TPI 287 at Brain Tumor Biotech Summit

CNS Pharmaceuticals (CNSP) announced that Sandra Silberman, Chief Medical Officer, will present at the Lenox Hill Hospital, Department...

2M ago

CNSP

CNS Pharmaceuticals price target raised to $7 from $4 at Alliance Global Partners

Alliance Global Partners analyst James Molloy raised the firm’s price target on CNS Pharmaceuticals (CNSP) to $7 from...

3M ago

CNSP

CNS Pharmaceuticals reports Q1 EPS ($1.58) vs. ($1,020.48) last year

“Our company remains focused as tightly as ever on neuro-oncology drug development. We are off to a very...

3M ago

CNSP

CNS Pharmaceuticals sees cash runway into 2h26

As of March 31, 2025, the Company had cash of approximately $13.1 million. Subsequent to the end of...

3M ago

CNSP

CNS Pharmaceuticals Raises $5M in Public Offering

The latest update is out from CNS Pharmaceuticals ( ($CNSP) ). On May 13, 2025, CNS Pharmaceuticals entered...

3M ago

CNSP

CNS Pharmaceuticals acquires Orphan Drug Designation for TPI 287

CNS Pharmaceuticals (CNSP) announced the successful transfer from Cortice Biosciences of Orphan Drug Designation for TPI 287. The...

3M ago

CNSP

CNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants

A.G.P. is sole placement agent. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...

4M ago

CNSP

CNS Pharmaceuticals Advances TPI 287 for Glioblastoma

CNS Pharmaceuticals ( ($CNSP) ) has shared an update. On April 9, 2025, CNS Pharmaceuticals announced its ongoing...

4M ago

CNSP

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year

“Oncology drug development can be complex and challenging, but the GBM patients who live with this devastating condition...

4M ago

CNSP

CNSP FAQ

What was Cns Pharmaceuticals, Inc.’s price range in the past 12 months?

Cns Pharmaceuticals, Inc. lowest stock price was $6.66 and its highest was $221.40 in the past 12 months.

What is Cns Pharmaceuticals, Inc.’s market cap?

Cns Pharmaceuticals, Inc.’s market cap is $3.55M.

When is Cns Pharmaceuticals, Inc.’s upcoming earnings report date?

Cns Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 18, 2025 which is in 9 days.

How were Cns Pharmaceuticals, Inc.’s earnings last quarter?

Cns Pharmaceuticals, Inc. released its earnings results on May 16, 2025. The company reported -$18.96 earnings per share for the quarter, beating the consensus estimate of -$24 by $5.04.

Is Cns Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts Cns Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cns Pharmaceuticals, Inc. pay dividends?

Cns Pharmaceuticals, Inc. does not currently pay dividends.

What is Cns Pharmaceuticals, Inc.’s EPS estimate?

Cns Pharmaceuticals, Inc.’s EPS estimate is -9.6.

How many shares outstanding does Cns Pharmaceuticals, Inc. have?

Cns Pharmaceuticals, Inc. has 529,829 shares outstanding.

What happened to Cns Pharmaceuticals, Inc.’s price movement after its last earnings report?

Cns Pharmaceuticals, Inc. reported an EPS of -$18.96 in its last earnings report, beating expectations of -$24. Following the earnings report the stock price went up 1.587%.

Which hedge fund is a major shareholder of Cns Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in CNSP

CNS Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

-477.53%

Trailing 12-Months

Asset Growth

727.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cns Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing novel treatments for brain tumors. The company is particularly dedicated to advancing its lead drug candidate, Berubicin, which is being investigated for the treatment of glioblastoma multiforme, a highly aggressive form of brain cancer. CNS Pharmaceuticals operates in the biopharmaceutical sector and is committed to addressing unmet medical needs through innovative research and development.

CNS Pharmaceuticals (CNSP) Earnings & Revenues

Historic Earnings Reports

CNSP Stock 12 Month Forecast

Average Price Target

$84.00

▲(1153.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","828006":"$828,006","1656001":"$1,656,001","414008.5":"$414,008.5","1242003.5":"$1,242,003.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$84.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,414008.5,828006,1242003.5,1656001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2022","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,18.203076923076924,23.686153846153847,29.169230769230772,34.652307692307694,40.135384615384616,45.61846153846154,51.10153846153846,56.58461538461538,62.067692307692305,67.55076923076923,73.03384615384616,78.51692307692308,{"y":84,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,18.203076923076924,23.686153846153847,29.169230769230772,34.652307692307694,40.135384615384616,45.61846153846154,51.10153846153846,56.58461538461538,62.067692307692305,67.55076923076923,73.03384615384616,78.51692307692308,{"y":84,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,18.203076923076924,23.686153846153847,29.169230769230772,34.652307692307694,40.135384615384616,45.61846153846154,51.10153846153846,56.58461538461538,62.067692307692305,67.55076923076923,73.03384615384616,78.51692307692308,{"y":84,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1656000.4,"date":1622505600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1530000.3,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":521460,"date":1643673600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298980,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198000.03,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48300,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.56,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.14,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":72.24,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.16,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.48,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >